The prevalence of aspirin resistance in patients with metabolic syndrome

Özcan ÖZDEMİR, Serkan TOPALOĞLU, Serkan ÇAY, Sezgin ÖZTÜRK, Bilal GEYİK, Göksel ÇAĞIRCI, Dursun ARAS

Özet

Amaç: Günümüzde aspirin metabolik sendromlu (MetS) hastalarda birincil korumada önerilmektedir. Bu çalışmada MetS’li hastalarda aspirine direnç araştırıldı.Çalışma planı: Çalışmaya, Uluslararası Diyabet Federasyonu ölçütlerine göre MetS tanısı konan 32 hasta (23 erkek, 9 kadın; ort. yaş 60.7±11.4) alındı. Tüm hastalarda aspirine direnç PFA-100 (Platelet Function Analyzer) yöntemiyle araştırıldı. Sonuçlar, MetS bulunmayan 30 hastadan (16 erkek, 14 kadın; ort. yaş 61.6±7.3) oluşan kontrol grubuyla karşılaştırıldı. PFA-100 analizi sırasında tüm hastalar aspirin kullanmaktaydı.Bulgular: Aspirine direnç her iki gruptan toplam 21 hastada (%33.9) görüldü. Metabolik sendrom grubunda direnç oranı %46.9 iken, kontrol grubunda bu oran %20 idi ve fark anlamlı bulundu (p=0.033). Aspirine direnç görülmeyenlerle karşılaştırıldığında, dirençli hastalarda açlık kan şekeri düzeyi anlamlı derecede yüksek bulunurken (102.0±14.6 mgr/dl ve 95.3±9.9 mgr/dl; p=0.036), bel çevresi ölçümleri de daha yüksek idi (97.4±14.1 cm ve 89.7±15.0 cm; p=0.053). Çokdeğişkenli lojistik regresyon analizinde aspirine direnç gelişimini anlamlı derecede etkileyen faktörler şunlardı: MetS (OR 0.28, %95 GA 0.09-0.88; p=0.029), açlık kan şekeri (OR 0.95, %95 GA 0.91-0.99; p=0.045), ürik asit (OR 0.46, %95 GA 0.28-0.76; p=0.002), gama-glutamil transferaz (OR 1.04, %95 GA 1.00-1.08; p=0.043), yüksek duyarlıklı C-reaktif protein (OR 1.07, %95 GA 1.01-1.12; p=0.015) ve trombosit sayısı (OR 0.99, %95 GA 0.98-0.99; p=0.034).

Abstract

Objectives: Aspirin is recommended for primary prevention in patients with metabolic syndrome (MetS). In this study, we evaluated aspirin resistance in MetS patients. Study design: The study included 32 patients (23 males, 9 females; mean age 60.7±11.4 years) with the diagnosis of MetS, according to the criteria of the International Diabetes Federation. Aspirin resistance was determined by the PFA-100 analysis (Platelet Function Analyzer). The results were compared with a control group of 30 patients (16 males, 14 females; mean age 61.6±7.3 years) without MetS. All the patients were taking aspirin at the time of the PFA-100 analysis. Results: Overall, 21 patients (33.9%) were aspirin nonresponders. The prevalence of aspirin resistance was 46.9% in the MetS group, and 20% in the control group. The difference between the two groups was statistically significant (p=0.033). Compared to aspirin responders, fasting blood glucose level was higher (102.0±14.6 mg/dl vs. 95.3±9.9 mg/dl; p=0.036) and waist circumference tended to be greater in nonresponders (97.4±14.1 cm vs. 89.7±15.0 cm; p=0.053). Multivariate logistic regression analysis showed that MetS (OR 0.28, 95% CI 0.09-0.88; p=0.029), fasting blood glucose (OR 0.95, 95% CI 0.91-0.99; p=0.045), uric acid (OR 0.46, 95% CI 0.28-0.76; p=0.002), gamma-glutamyl transferase (OR 1.04, 95% CI 1.00-1.08; p=0.043), high-sensitivity C-reactive protein (OR 1.07, 95% CI 1.01-1.12; p=0.015) levels and platelet count (OR 0.99, 95% CI 0.98-0.99; p=0.034) significantly affected aspirin resistance. Conclusion: Our results show that a significant proportion of MetS patients will not benefit from aspirin use due to high aspirin resistance.